Synthetic fragment of thymosin β4. Promotes systemic actin-mediated cell migration to injury sites.
Active fragment of the naturally occurring 43-amino acid Thymosin β4 protein. Binds G-actin and accelerates cell migration, angiogenesis, and inflammation modulation. Cardiac and dermal wound studies dominate the literature; orthopedic claims are mostly extrapolated.
Banned by WADA for sport. Long-term human safety data limited. Watch for impurity profiles in compounded sources.
Active heptapeptide region of full Thymosin β4 (43 aa).
Stack doesn't rank peptides — we surface the diversity of opinion. Each card paraphrases a public-record stance from a named source. Where they conflict is where you should slow down and read both.
RegeneRx ran multiple Phase 2 trials of Thymosin β4 (TB-500's parent molecule) for dry-eye disease, pressure ulcers, and cardiac repair through 2020. Mixed results. The trials were sponsored, not independent. Most data behind paywalls.
B-tier when paired with BPC-157 — "the Wolverine Stack." Situational, only run for an actual injury. Notes WADA bans TB-500 for sport, so athletes in tested federations cannot use.
Documents TB-500 use for systemic recovery and tendon injury alongside BPC-157. Pre-2023 US compounding-pharmacy clinical use was meaningful before the Cat-2 ban. Post-ban access is largely grey-market.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 2-5 mg · twice weekly, subcutaneous
Draw volume exceeds 100 units (1 mL). Either reduce dose or split into multiple injections.
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
How much a first cycle actually costs across the channels people use. Pick the protocol length you're considering — Stack multiplies the monthly band by cycle weeks. Same caveats apply: ranges are facts, quality varies, this is not legal advice.
Numbers reflect publicly-advertised price ranges, not vendor quotes. Insurance, prescription costs, and shipping aren't included. Channels marked unavailable are filtered out.
See pharmacies for this compound →Approximate monthly cost across the channels users actually consider — brand FDA-approved retail, US 503A compounding, Mexican pharmacies, MX farmacias magistrales, and the research-grey market. Stack lists ranges, not vendor names. Quality varies wildly across channels — see each band's note.
Not currently legal in US — same Cat-2 status as BPC-157. PCAC review July 2026.
As of 2026-04MX farmacias magistrales — typically more expensive than BPC-157 due to peptide complexity.
As of 2026-04Research-grey range. WADA-banned for sport — athletes in tested federations should avoid entirely.
As of 2026-04Public-source attribution across the production + distribution chain. Stack does not endorse vendors — this is who is in the chain, not which one is best.
BPC-157 · TB-500 · Sermorelin · CJC-1295/Ipamorelin · Semaglutide · Tirzepatide
Houston-based 503A compounding pharmacy, one of the largest in the US peptide compounding market.
BPC-157 · TB-500 · Sermorelin · CJC-1295/Ipamorelin
One of the most consistently recommended vendors on r/Peptides since the Peptide Sciences shutdown (March 2026). Third-party COA published per batch. HPLC purity ≥99%.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Long-established US vendor (7+ years). Broad catalog including GHRPs, GHRHs, and cognitive peptides. Third-party HPLC and mass-spec COA per batch. Active Finnrick Analytics coverage.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Newer vendor with fast turnaround and competitive pricing. Third-party COA on all products. Building Finnrick coverage. Frequently recommended post-Peptide Sciences shutdown.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Established vendor with multi-year community track record. Offers peptide blends (Wolverine Stack, etc.) alongside singles. Third-party COA available on request.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Known for above-average catalog depth, including harder-to-find compounds (SS-31, humanin, Foxo4-DRI). Third-party HPLC published. Active Finnrick coverage.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Clean storefront, competitive pricing, strong community mentions. Third-party COA on most products. Ships to US with fast turnaround.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
Tampa-based telehealth clinic specializing in hormone and peptide therapy. Prescribing provider + compounding pharmacy fulfillment. BPC-157, CJC/Ipa, Ipamorelin, PT-141, Sermorelin. Prescription required.
For laboratory use only / not for human consumption. Stack may earn affiliate commissions.
FDA Cat. 2 removed Apr 2026 — PCAC review Jul 23-24, 2026
FDA's Pharmacy Compounding Advisory Committee scheduled to review the first cohort of peptides removed from Category 2 in April 2026. The 7 peptides on this docket are the highest-profile community names — BPC-157, TB-500, MOTS-c, Epitalon, DSIP, Semax, KPV.
FDA published a Federal Register notice on April 15 2026 removing 12 peptides from the Category 2 ('significant safety concerns') compounding list, paving the way for PCAC review for inclusion on the 503A bulks list. Peptides removed: BPC-157, TB-500, Epitalon, GHK-Cu (injectable), MOTS-c, DSIP, Dihexa Acetate, MK-677, Melanotan II, KPV, Semax, LL-37.
FDA's Pharmacy Compounding Advisory Committee categorized a wide list of peptides as Category 2 ('significant safety concerns'), effectively banning their compounding at 503A and 503B pharmacies. Affected: BPC-157, TB-500, Epitalon, GHK-Cu, MOTS-c, DSIP, Dihexa, MK-677, Melanotan II, KPV, Semax, Selank, LL-37 and others.
Australia's Therapeutic Goods Administration classified TB-500 (Thymosin Beta-4) as Schedule 4 (prescription-only). Possession or sale without prescription carries criminal penalties.
COFEPRIS regulates Mexican farmacias magistrales (compounding pharmacies) under different rules than the US 503A bulks-list framework. Several Mexican compounding pharmacies prepare BPC-157, TB-500, CJC-1295/Ipamorelin, Tesamorelin, and GHK-Cu without the FDA Category 2 ban that has constrained US compounding since 2023.
World Anti-Doping Agency added TB-500 (Thymosin Beta-4) to the prohibited list under S2.5 (TB-500). Banned in and out of competition for athletes subject to WADA jurisdiction.